NCT04514159View on ClinicalTrials.gov

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Breast Cancer
Interventions
DRUG

ZN-c5

ZN-c5 is the study drug.

DRUG

Abemaciclib

Abemaciclib (VERZENIO®) is an approved drug.

Trial Locations (5)

29414

Site 1, Charleston

85234

Site 2, Gilbert

86-300

Site 6, Grudziądz

30-348

Site 4, Krakow

93-513

Site 5, Lodz

All Listed Sponsors
lead

Zeno Alpha Inc.

INDUSTRY

NCT04514159 - A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | Biotech Hunter | Biotech Hunter